1. Pharmaceutical CGMPs for the 21st century – A Risk-Based Approach. Final report (2004) US Food and Drug Administration. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Manufacturing/QuestionsandAnswersonCurrentGoodManufacturingPracticescGMPforDrugs/UCM176374.pdf . Accessed 14 Jun 2012
2. Guidance for Industry. PAT - A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance (2004) US Food and Drug Administration. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070305.pdf . Accessed 14 Jun 2012
3. Guidance for Industry. Q8(R2) Pharmaceutical Development (2009) US Food and Drug Administration. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073507.pdf . Accessed 14 Jun 2012
4. ICH Harmonised Tripartite Guideline. Pharmaceutical Development Q8(R2) (2009) International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf . Accessed 14 Jun 2012
5. ICH Harmonised Tripartite Guideline. Quality Risk Management Q9 (2005) International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q9/Step4/Q9_Guideline.pdf . Accessed 14 Jun 2012